How clinical research sites can switch to an electronic investigator site file without giving up control

Can a research site own its electronic regulatory records?

Yes. A site-owned electronic investigator site file keeps the site's regulatory records under its own control, across every sponsor and every study, including after a study closes.

Almost every electronic system a site has encountered was required by a sponsor, which is why systems can often feel “borrowed”. They aren’t flexible to your workflows, they’re repetitive, and they generally aren’t built with sites in mind. An electronic investigator site file (eISF) your site licenses is different.

A site-owned electronic investigator site file is an established category. Your institution licenses it, configures it to your own structure and your own SOPs, and holds the records in it across every sponsor and every study you run. Sponsors and monitors are granted access to what you choose to show them, for as long as you choose to show it. When the study closes and the sponsor's portal is decommissioned, nothing happens to your record, because your record was never in their portal. Florence eBinders works this way: the site sets up its binders and grants each monitor role-based access to the studies they oversee.

With an eISF, the essential records are already yours. Under GCP the investigator and the institution hold them, and that responsibility doesn't transfer to a sponsor because the sponsor provided a tool. ICH E6(R3) states that the investigator and institution should have control of the essential records they generate before and during the trial (section 2.12.11). A sponsor can require that you give them access. They can't require that you stop keeping your own record.

How long do EU sites have to keep clinical trial records?

At least 25 years after the trial ends, for the site as well as the sponsor.

Article 58 is the reason you couldn't stop anyway. It places the archiving obligation on the investigator as well as the sponsor: the content of the trial master file has to be kept for at least twenty five years after the trial ends, held so it stays readily available and accessible to competent authorities on request, on media that keeps it complete and legible across that whole period, with any alteration traceable.

Twenty five years outlasts most sponsor relationships and most staff contracts. And so an electronic system provided by a sponsor that cuts off the site’s access at closeout was never going to satisfy regulations, which is why the binder is still in your office. EMA's guideline on computerised systems also says the sponsor should not have exclusive control of data entered in a computerised system.

Do EU rules require sites to use electronic systems?

No, electronic record keeping is optional under current EU guidance.

None of this is a regulatory leap. The EMA's guideline on computerised systems and electronic data in clinical trials states plainly that there's no requirement or expectation that sponsors and investigators use computerised systems.

Instead, the guideline describes what a site must be able to demonstrate once it works electronically: traceability across the record's lifecycle (which is the addition ALCOA++, the data integrity principles the guideline applies to trial records, made explicit) and an audit trail that captures creation and every subsequent modification, secure, computer generated, and timestamped.

A purpose-built digital system produces those as a matter of course. A paper process produces them through sustained human discipline, every day, across every study.

So the choice was never paper against digital. Your site is already both. The choice is which half you control.

What are the benefits of an electronic investigator site file for sites?

More study capacity without more headcount

The return is capacity, not compliance. Your records were already compliant. What changes by shifting to an electronic solution is how much time your team is devoting to the trial itself instead of administrative tasks.

Every study and every sponsor you add brings more administrative work, and that is usually what limits how many studies a site can run.

A digital regulatory record changes that, because the system records actions as the work happens, instead of your team assembling that proof afterwards.

The same team absorbs more studies without the increase in headcount you'd otherwise need to ask for.

Keeping site knowledge when staff change

Turnover is a real problem in offices funded through temporary contracts and grant cycles.

When the knowledge about how paper binders are organized and stored lives in a coordinator’s head, the knowledge leaves when they do.

When the structure is built into the system, a new coordinator inherits a working environment rather than a reconstruction project, and the handover takes days rather than months.

Something as simple as a coordinator being out of office during a surprise inspection can be mitigated by having all papers stored centrally and digitally.

Easier remote monitoring for sponsors

Providing a digital record of your ISF makes monitoring a trial faster, easier, and cheaper for sponsors.

Monitoring is among the largest line items in a trial budget, and sponsors are under sustained pressure to reduce it. An eISF allows for remote monitoring, which stays compliant with E6(R3) while reducing friction between your site and your sponsor. In eBinders, for example, monitors can review site documents before an on-site visit, within the access the site grants.

Sites that can support remote monitoring are cheaper to run trials with, and sponsors increasingly ask about it at selection. A site with its own system answers that question before it's asked, and answers it the same way for every sponsor rather than renegotiating each time. That site gets selected for more studies.

How do you introduce an eISF at a hospital or research institute?

Introducing an eISF to your site can feel overwhelming. Most tools are provided by the sponsor, so there isn’t always a clear path to adopting a new solution.

1. Work out who the buyer actually is, first

   At many hospitals the contracting entity for research isn't the hospital administration but the affiliated research foundation or health research institute, which usually has more procurement flexibility than the hospital itself. Establishing which entity signs, and whether the spend sits above or below the threshold that triggers a formal tender, will tell you more about your timeline than any other single question. Ask it in week one rather than month four.

2. Expect your IT director to ask why you need this if you already have Fundanet

   A clinical trial management system (CTMS) such as Fundanet, the research management platform from Spanish vendor Semicrol, tracks studies, milestones, budgets and recruitment. An eISF holds the regulatory documents themselves. Different jobs, and the right system integrates with the CTMS your institution already runs rather than duplicating it, so nobody ends up maintaining two systems of record. Make that integration a requirement rather than a hope, and ask to see it working before you sign.

   Florence integrates with the research management and hospital systems your site depends on. Our team scopes each connection with yours, starting simple and expanding as your technology evolves. Talk to us about the systems you use today.

3. Give quality and legal what they'll ask for, early

   Validation documentation, the audit trail specification, user access and role management, and where the data physically sits. EU data residency and GDPR handling will come up, and your prospective vendors must be able to produce that package on request.

4. Ask about the sponsor side

   Many sponsors prefer working with sites that already have an eISF, and in some cases the cost is reimbursable through the trial budget. Worth raising with one or two of your closest sponsors before you go to your institution, because a sponsor who says they'd support it changes the internal argument considerably.

5. Protect yourself on price

   Ask what happens as your study volume grows, and get the answer in the contract rather than in a conversation. Sites that built their workflow on a platform and then met a pricing change in year three had no leverage and no budget flexibility, which is a particularly difficult position for a publicly funded institution.

6. Then start with one study

   Ideally a new one, ideally with a sponsor you have a good relationship with. Run its regulatory documents in the system while everything else continues as it is. Within a single start-up cycle you'll know whether your coordinators find it easier, whether your investigator will actually use it, and what your IT and quality colleagues need in order to approve a wider rollout.

The question underneath all of it

Digital record keeping for a trial is not currently a mandatory requirement in the EU. But that may not be true forever.

What regulations do currently require is that your institution can produce its essential records, complete and legible, for at least twenty five years. You're meeting that obligation with the one part of your record you own, and doing the rest of your work in systems that end when the study does.

The question isn't whether to go electronic. You already did. It's whether the electronic half should belong to you.